TQB2450 injection
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Xianhai Mao
Conditions
Adjuvant TherapyAdvanced Biliary Adenocarcinoma/Hepatocellular CarcinomaAdvanced Biliary CancerAdvanced Endometrial CancerHepatocellular CarcinomaNon Small Cell Lung CancerRecurrent Platinum-resistant Ovarian CancerSarcoma of Uterus
Phase 1
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
NCT03825705
Start: 2019-04-23End: 2021-01-01Target: 60Updated: 2019-10-31
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
NCT06116240
Start: 2022-09-02End: 2023-12-31Target: 135Updated: 2023-11-03
Phase 2
TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
NCT05111366
Start: 2022-01-06End: 2024-05-20Target: 37Updated: 2022-05-04
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
TerminatedNCT05481645
Start: 2022-08-26End: 2025-11-30Updated: 2026-01-09
Phase 3
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
NCT04809142
Start: 2021-02-04End: 2023-02-01Target: 392Updated: 2021-03-22
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
NCT04964479
Start: 2021-08-06End: 2023-03-31Target: 375Updated: 2021-08-20
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
NCT05145218
Start: 2021-09-28End: 2024-12-31Target: 405Updated: 2021-12-08